Natural products as potential lead compounds to develop new antiviral drugs over the past decade
JH Zhao, YW Wang, J Yang, ZJ Tong, JZ Wu… - European Journal of …, 2023 - Elsevier
Virus infection has been one of the main causes of human death since the ancient times.
Even though more and more antiviral drugs have been approved in clinic, long-term use can …
Even though more and more antiviral drugs have been approved in clinic, long-term use can …
Assessing the environmental occurrence of the anthropogenic contaminant trifluoroacetic acid (TFA)
F Freeling, MK Björnsdotter - Current Opinion in Green and Sustainable …, 2023 - Elsevier
Trifluoroacetic acid (TFA) is a very persistent contaminant that has gained attention due to its
multitude of anthropogenic sources, widespread occurrence in the environment, and …
multitude of anthropogenic sources, widespread occurrence in the environment, and …
Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19
Objective To investigate the association between nirmatrelvir plus ritonavir (NMV-r) and the
outcomes of non-hospitalized obese patients with coronavirus disease 2019 (COVID-19) …
outcomes of non-hospitalized obese patients with coronavirus disease 2019 (COVID-19) …
A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir/ritonavir
J Gerhart, DS Cox, RSP Singh, PLS Chan… - Clinical …, 2024 - Springer
Nirmatrelvir is a potent and selective inhibitor of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus …
coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus …
[HTML][HTML] The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years: a cohort study
G Yan, J Zhou, H Zhu, Y Chen, Y Lu… - Annals of …, 2022 - ncbi.nlm.nih.gov
Background Paxlovid is recognized as an effective medication in preventing the progression
of coronavirus disease of 2019 (COVID-19) to severe form in adults; however, its efficacy …
of coronavirus disease of 2019 (COVID-19) to severe form in adults; however, its efficacy …
Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: a review of immunosuppressant adjustment strategies
Y Tang, Y Li, T Song - Frontiers in Immunology, 2023 - frontiersin.org
The coronavirus disease 2019 (COVID-19) pandemic has caused a significant burden of
morbidity and mortality worldwide, with solid organ transplant recipients (SOTRs) being …
morbidity and mortality worldwide, with solid organ transplant recipients (SOTRs) being …
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
T Zhang, W Tian, S Wei, X Lu, J An, S He… - … Hematology & Oncology, 2023 - Springer
The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge
on public health systems. Despite the measures put in place to contain it, COVID-19 is likely …
on public health systems. Despite the measures put in place to contain it, COVID-19 is likely …
Physiologically‐based pharmacokinetic modeling‐guided dose Management of Oral Anticoagulants when initiating Nirmatrelvir/ritonavir (Paxlovid) for COVID‐19 …
Patients with coronavirus disease 2019 (COVID‐19) with cardiovascular diseases who are
at higher risk of progressing to critical illness should be treated with nirmatrelvir/ritonavir …
at higher risk of progressing to critical illness should be treated with nirmatrelvir/ritonavir …
SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads
We report here the synthesis and biological evaluation of a series of small molecule SARS-
CoV-2 PLpro inhibitors. We compared the activity of selected compounds in both SARS-CoV …
CoV-2 PLpro inhibitors. We compared the activity of selected compounds in both SARS-CoV …